Fairvalue-Calculator Fairvalue-Calculator
EN DE

Aprea Therapeutics, Inc (APRE) Fair Value & Analysis

Healthcare · US · Market cap $9.5M

Price$0.8083
Fair Value$0.9700
Upside+20.0%
Quality95/100
Evidence: Low Range $0.6400 – $1.22

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Aprea Therapeutics, Inc (APRE) currently trades at $0.8083, while our model-based Fair Value estimate is $0.9700 — implying the stock looks roughly 20.0% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Aprea Therapeutics, Inc (APRE) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $0.9700 versus a price of $0.8083 — about +20% (undervalued). Model-based estimate, not financial advice.
What is the fair value of APRE?
Our 21-model fair value for Aprea Therapeutics, Inc is $0.9700 (as of Jun 25, 2026), built from audited fundamentals. The current price is $0.8083.
What is the quality score of APRE?
Aprea Therapeutics, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.